This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Socinski, M. A. Articles by Rosenman, J. Search for Related Content PubMed PubMed Citation Articles by Socinski, M. A. Articles by Rosenman, J.

Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: A Preliminary Report of a Phase I Dose Escalation Trial from the Carolina Conformal Therapy Consortium

Departments of Radiation Oncology, Medical Oncology, and Biometry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA; Wake Forest University, Winston Salem, North Carolina, USA; and Medical University of South Carolina, Columbia, South Carolina, USA

Correspondence: M. A. Socinski, M.D., Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, Division of Hematology/Oncology, CB 7305, Chapel Hill, North Carolina 27514, USA. Telephone: 919-966-4431; Fax: 919-966-6735; e-mail: socinski{at}med.unc.edu

The maximum tolerated dose of conformal radiation therapy delivered at 1.6 Gy bid is being assessed in patients with unresectable stage IIB-IIIB non-small cell lung cancer who have been treated with induction regimens consisting of carboplatin plus paclitaxel or carboplatin plus vinorelbine. Data from the early stages of this parallel phase I study show that the two induction regimens are similar in toxicity and that both induce partial responses in 45% of patients. Both regimens can be followed by conformal radiotherapy using an accelerated hyperfractionated schedule to a dose of at least 80 Gy without experiencing unacceptable toxicity. Key morbidity observed thus far has involved the esophagus. Further cohorts of patients will receive higher doses of conformal radiotherapy (in 6.4 Gy increments) until the maximum tolerated dose is reached.

Key Words. Carboplatin • Paclitaxel • Vinorelbine • AHCRT • TRT

This article has been cited by other articles:

				D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]

				M. J. Edelman New Directions in the Treatment of Non-Small Cell Lung Cancer: An Overview Oncologist, February 1, 2001; 6(2008): 1 - 3. [Abstract] [Full Text] [PDF]